New study checks drug interactions for advanced breast cancer treatment
NCT ID NCT06710990
First seen Jun 07, 2026 · Last updated Jun 10, 2026 · Updated 2 times
Summary
This study looked at how two common drugs (ritonavir and itraconazole) change the way the body processes a new experimental drug called SHR-A1811 in people with advanced HER2-positive breast cancer. Seventeen participants received the drug alone and then with each of the other medications to measure safety and blood levels. The goal was to understand potential drug interactions, not to test if the drug works as a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510200, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.